GlassScriptPhysician profile
Kurt D Miller
NPI 1417906686
$3,275.29
in general payments reported to CMS, 2019-2025
29 companies · $449 in 2025
The $449 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $154 · 2021: $386 · 2022: $466 · 2023: $390 · 2024: $296 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.38 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $366.94 | 2022-2025 | |
| Siemens Medical Solutions USA, INC. | $214.48 | 2023-2025 | Embozene, Microthermx Microwave Ablation System, Oncozene |
| Therapeuticsmd, INC. | $212.57 | 2019-2020 | |
| Astellas Pharma US INC | $185.02 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $145.38 | 2019-2025 | |
| Exeltis, USA INC. | $131.32 | 2019-2025 | Slynd |
| Lupin INC. | $130.51 | 2019 | |
| Hologic Sales and Service, LLC | $120.70 | 2019-2025 | Aptima |
| Myovant Sciences INC. | $119.77 | 2021 | |
| Pfizer INC. | $100.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $86.25 | 2019 | |
| Biogen, INC. | $64.50 | 2024 | Zurzuvae |
| Sumitomo Pharma America, INC. | $63.56 | 2023-2025 | Myfembree |
| Myriad Women'S Health, INC. | $44.17 | 2023 | Myrisk |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $40.91 | 2019-2022 | |
| Avion Pharmaceuticals | $39.17 | 2019-2022 | |
| Evofem Biosciences, INC. | $28.57 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $24.72 | 2022 | |
| Millicent US INC | $22.36 | 2025 | Intrarosa |
| Minerva Surgical, INC | $21.07 | 2023 | |
| Allergan, INC. | $19.75 | 2019 | |
| Organon LLC | $19.67 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.74 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $16.12 | 2022 | |
| Coopersurgical, INC. | $13.59 | 2025 | Paragard T 380a |
| Covidien LP | $12.90 | 2019 | |
| Amgen INC. | $12.86 | 2019 | |
| Ethicon US, LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.